Anti-viral compounds and methods for administration thereof

Abstract

This invention relates to the use of anti viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS˜CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drags formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations that are incorporated into pulmonary and oral delivery systems.

What is claimed is: 
     
         1 . A pharmaceutical composition, comprising:
 two chemically linked anti-viral agents wherein the first anti-viral agent is selected from the group consisting of entry inhibitors, RNA-dependent RNA polymerase inhibitors, protease inhibitors, glucocorticoid receptor modulators and androgen receptor modulators, and pharmaceutically acceptable salts thereof, and the second anti-viral agent is selected from the group consisting of RNA-dependent RNA polymerase inhibitors, protease inhibitors, glucocorticoid receptor modulators and androgen receptor modulators, endosome acidifying MicroRNA inhibitors, and pharmaceutically acceptable salts thereof.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the entry inhibitor comprises valsartan or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the RNA-dependent RNA polymerase inhibitor is selected from the group consisting of rifampin, myricetin, remdesivir, the ribose active metabolite of remdesivir, and pharmaceutically acceptable salts thereof. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the protease inhibitor is selected from the group consisting of rupintrivir, ritonavir, lopinavir, and pharmaceutically acceptable salts thereof. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the glucocorticoid receptor modulators and androgen receptor modulator is selected from the group consisting of dexamethasone, mifepristone, relacorilant, miricorilant, and pharmaceutically acceptable salts thereof. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the endosome acidifying MicroRNA inhibitor comprises hydroxychloroquine or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The pharmaceutical composition of  claim 1 , further comprising a third chemically linked anti-viral agent selected from the group consisting of protease inhibitors and pharmaceutically acceptable salts thereof. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the third anti-viral agent is selected from the group consisting of rupintrivir, ritonavir, lopinavir, and pharmaceutically acceptable salts thereof. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the first anti-viral agent comprises remdesivir, the ribose alcohol active metabolite of remdesivir, or pharmaceutically acceptable salts thereof, and the second anti-viral agent comprises hydroxychloroquine or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the first anti-viral agent comprises remdesivir, the ribose alcohol active metabolite of remdesivir, or a pharmaceutically acceptable salt thereof, and the second anti-viral agent comprises dexamethasone or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the two chemically linked anti-viral agents are combined with a carrier suitable for respiratory administration to a patient via vaporization wherein the heat of vaporization is capable of de-coupling the two chemically linked anti-viral agents. 
     
     
         12 . The pharmaceutical composition of  claim 7 , wherein the three chemically linked anti viral agents are combined with a carrier suitable for respiratory administration to a patient via vaporization wherein the heat of vaporization is capable of de-linking the three chemically linked anti-viral agents. 
     
     
         13 . The pharmaceutical composition of  claim 1 , further comprising an anti-bacterial, anti-fungal, or anti-protozoal agent. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the chemical link between anti-viral agents comprises at least one carbamate or carbonate group. 
     
     
         15 . A method of treating a viral disease, comprising the step of administering to a patient the pharmaceutical composition of  claim 1  combined with a carrier suitable for respiratory administration via vaporization wherein the heat of vaporization decouples the chemically linked anti-viral agents. 
     
     
         16 . The method of  claim 15 , wherein the disease is selected from the group consisting of SARS, MERS, and SARS-CoV-2. 
     
     
         17 . The method of  claim 15 , wherein the first anti-viral agent comprises remdesivir, the ribose active metabolite of remdesivir, or pharmaceutically acceptable salts thereof, and the second anti-viral agent comprises hydroxychloroquine or a pharmaceutically acceptable salt thereof. 
     
     
         18 . The method of  claim 15 , wherein the first anti-viral agent comprises remdesivir, the ribose active metabolite of remdesivir, or a pharmaceutically acceptable salt thereof, and the second anti-viral agent comprises dexamethasone or a pharmaceutically acceptable salt thereof. 
     
     
         19 . The method of  claim 15 , wherein the pharmaceutical composition comprises three chemically linked anti-viral agents. 
     
     
         20 . The method of  claim 15 , wherein the pharmaceutical composition further comprises an anti-bacterial, anti-fungal, or anti-protozoal agent.